UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 204

Sortiert nach

Herpes simplex virus alters Alzheimer's disease biomarkers ‐ A hypothesis paper

Alzheimer's & dementia, 2023-05, Vol.19 (5), p.2117-2134

2023

Volltextzugriff (PDF)

The heritability of blood‐based biomarkers related to risk of Alzheimer's disease in a population‐based sample of early old‐age men

Alzheimer's & dementia, 2024-01, Vol.20 (1), p.356-365

2024

Volltextzugriff (PDF)

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort

NeuroImage clinical, 2018-01, Vol.18, p.167-177

2018

Volltextzugriff (PDF)

Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin

Alzheimer's & dementia, 2019-11, Vol.15 (11), p.1437-1447

2019

Volltextzugriff (PDF)

Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes

European journal of neurology, 2022-06, Vol.29 (6), p.1630-1642

2022

Volltextzugriff (PDF)

Predictors for early‐onset psychotic symptoms in patients newly diagnosed with Parkinson's disease without psychosis at baseline: A 5‐year cohort study

CNS neuroscience & therapeutics, 2024-03, Vol.30 (3), p.e14651-n/a

2024

Volltextzugriff (PDF)

Neuropsychological Testing and Machine Learning Distinguish Alzheimer's Disease from Other Causes for Cognitive Impairment

Frontiers in aging neuroscience, 2017-04, Vol.9, p.114-114

2017

Volltextzugriff (PDF)

Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: Mediation with hippocampal volume

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2022, Vol.14 (1), p.e12349-n/a

2022

Volltextzugriff (PDF)

Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression

Neural regeneration research, 2016-06, Vol.11 (6), p.944-950

2016

Volltextzugriff (PDF)

Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone

Acta neurologica Scandinavica, 2011-04, Vol.123 (4), p.252-256

2011

Volltextzugriff (PDF)

Biomarkers of brain injury after cardiac arrest; a statistical analysis plan from the TTM2 trial biobank investigators

Resuscitation plus, 2022-06, Vol.10, p.100258-100258, Article 100258

2022

Volltextzugriff (PDF)

Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration

Brain (London, England : 1878), 2023-03, Vol.146 (3), p.1152-1165

2023

Volltextzugriff (PDF)

CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease

European journal of neurology, 2008-11, Vol.15 (11), p.1155-1162

2008

Volltextzugriff (PDF)

Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities

Alzheimer's & dementia, 2022-06, Vol.18 (6), p.1128-1140

2022

Volltextzugriff (PDF)

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

Alzheimer's & dementia, 2018-11, Vol.14 (11), p.1470-1481

2018

Volltextzugriff (PDF)

Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease

Journal of Alzheimer's disease, 2018-01, Vol.61 (4), p.1323

2018

Volltextzugriff (PDF)

Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity

European journal of neurology, 2021-10, Vol.28 (10), p.3324-3331

2021

Volltextzugriff (PDF)

Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy

Journal of Alzheimer's disease, 2018-01, Vol.61 (1), p.265

2018

Volltextzugriff (PDF)

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid

Clinical biochemistry, 2019-10, Vol.72, p.30-38

2019

Volltextzugriff (PDF)

Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging

Alzheimer's & dementia, 2023-10, Vol.19 (10), p.4498-4506

2023

Volltextzugriff (PDF)

Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia

Neurobiology of disease, 2023-10, Vol.186, p.106267-106267, Article 106267

2023

Volltextzugriff (PDF)

Preanalytical stability of plasma/serum brain-derived tau

Alzheimer's & dementia, 2023-10, Vol.19 (10), p.4764-4770

2023

Volltextzugriff (PDF)

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Alzheimer's & dementia, 2018-10, Vol.14 (10), p.1313-1333

2018

Volltextzugriff (PDF)

Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid β up to 90 Days after Traumatic Brain Injury

Journal of neurotrauma, 2017-01, Vol.34 (1), p.66

2017

Volltextzugriff (PDF)

Salivary Aβ1–42 may be a quick-tested biomarker for clinical use in Alzheimer’s disease: a meta-analysis

Journal of neurology, 2023-04, Vol.270 (4), p.1945-1954

2023

Volltextzugriff (PDF)

1 – 25 von 204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(184)
Mit Volltextzugriff
(167)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(161)
Life Sciences & Biomedicine
(149)
Neurosciences & Neurology
(114)
Total Tau
(108)
Neurosciences
(101)
Alzheimer's Disease
(100)
Humans
(96)
Biomarkers
(76)
Cerebrospinal Fluid
(70)
Clinical Neurology
(62)
Tau Proteins - Cerebrospinal Fluid
(58)
Female
(56)
Male
(56)
Aged
(52)
Neurology
(50)
Amyloid Beta-Peptides - Cerebrospinal Fluid
(47)
Biomarkers - Cerebrospinal Fluid
(46)
Tau Protein
(46)
Middle Aged
(43)
Phosphorylated Tau
(43)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Herpes simplex virus alters Alzheimer's disease biomarkers ‐ A hypothesis paper

The heritability of blood‐based biomarkers related to risk of Alzheimer's disease in a population‐based sample of early old‐age men

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort

Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin

Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes

Predictors for early‐onset psychotic symptoms in patients newly diagnosed with Parkinson's disease without psychosis at baseline: A 5‐year cohort study

Neuropsychological Testing and Machine Learning Distinguish Alzheimer's Disease from Other Causes for Cognitive Impairment

Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: Mediation with hippocampal volume

Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression

Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone

Biomarkers of brain injury after cardiac arrest; a statistical analysis plan from the TTM2 trial biobank investigators

Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration

CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease

Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease

Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity

Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid

Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging

Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia

Preanalytical stability of plasma/serum brain-derived tau

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid β up to 90 Days after Traumatic Brain Injury

Salivary Aβ1–42 may be a quick-tested biomarker for clinical use in Alzheimer’s disease: a meta-analysis

Suchergebnisse filtern